Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
TXG Analyst Ratings
Moderate Buy
6 Buy
6 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TXG Stock 12 Month Forecast
Average Price Target
$16.36
▲(73.86% Upside)
| Highest Price Target$26.00 | Average Price Target$16.36 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
Reiterated
03/04/25
Guggenheim
Reiterated
02/23/25
Morgan Stanley
Reiterated
02/14/25
Barclays
Reiterated
02/14/25
Bank of America Securities
Reiterated
02/13/25
J.P. Morgan
Reiterated
02/13/25
Stifel Nicolaus
Reiterated
02/13/25
Canaccord Genuity
Reiterated
02/13/25
Leerink Partners
Downgraded
02/13/25
TD Cowen
$18→$15
Hold
59.40%
Upside
Reiterated
02/12/25
Balanced Outlook Amid Revenue Growth and Market Risks: Hold Rating for 10x GenomicsWe believe further NIH-related downside remains (assuming the total budget is cut and indirect rate is also cut), and believe incorporating a bigger impact into the guide now (perhaps even another -1%) with the stock already down could have helped reduce investor uncertainty. That said, the initial guidance impact seems logical.
Jefferies
$19
Buy
101.91%
Upside
Reiterated
02/12/25
Positive Outlook for 10x Genomics Amid Strong Financials and Growth ProspectsWe see little middle ground, as bulls argue conservatism after tough few years and newer CFO set up for beats, while bears see NIH downside, competitive dynamics and little valuation support.
Goldman Sachs
$16→$14
Sell
48.78%
Upside
Reiterated
10/30/24
10X Genomics (TXG) PT Lowered to $14 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on 10X Genomics (NASDAQ: TXG) to $14.00 (from $16.00) while maintaining a Sell rating.
Deutsche Bank
$25
Hold
165.67%
Upside
Reiterated
08/09/24
10x Genomics: A Cautious Hold Amidst Revised Forecasts and Organizational Changes
Wolfe Research
―
Hold
―
Downgraded
06/27/24
10x Genomics (TXG) Receives a New Rating from a Top Analyst
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
Reiterated
03/04/25
Guggenheim
Reiterated
02/23/25
Morgan Stanley
Reiterated
02/14/25
Barclays
Reiterated
02/14/25
Bank of America Securities
Reiterated
02/13/25
J.P. Morgan
Reiterated
02/13/25
Stifel Nicolaus
Reiterated
02/13/25
Canaccord Genuity
Reiterated
02/13/25
Leerink Partners
Downgraded
02/13/25
TD Cowen
$18→$15
Hold
59.40%
Upside
Reiterated
02/12/25
Balanced Outlook Amid Revenue Growth and Market Risks: Hold Rating for 10x GenomicsWe believe further NIH-related downside remains (assuming the total budget is cut and indirect rate is also cut), and believe incorporating a bigger impact into the guide now (perhaps even another -1%) with the stock already down could have helped reduce investor uncertainty. That said, the initial guidance impact seems logical.
Jefferies
$19
Buy
101.91%
Upside
Reiterated
02/12/25
Positive Outlook for 10x Genomics Amid Strong Financials and Growth ProspectsWe see little middle ground, as bulls argue conservatism after tough few years and newer CFO set up for beats, while bears see NIH downside, competitive dynamics and little valuation support.
Goldman Sachs
$16→$14
Sell
48.78%
Upside
Reiterated
10/30/24
10X Genomics (TXG) PT Lowered to $14 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on 10X Genomics (NASDAQ: TXG) to $14.00 (from $16.00) while maintaining a Sell rating.
Deutsche Bank
$25
Hold
165.67%
Upside
Reiterated
08/09/24
10x Genomics: A Cautious Hold Amidst Revised Forecasts and Organizational Changes
Wolfe Research
―
Hold
―
Downgraded
06/27/24
10x Genomics (TXG) Receives a New Rating from a Top Analyst
TXG Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Jan 25
Feb 25
Mar 25
Strong Buy
8
6
6
6
6
Buy
10
9
10
5
5
Hold
11
8
11
8
8
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
30
24
28
19
19
Each month's total comprises the sum of three months' worth of ratings.
TXG Financial Forecast
TXG Stock Forecast FAQ
What is TXG’s average 12-month price target, according to analysts?
Based on analyst ratings, 10x Genomics Inc’s 12-month average price target is $16.36.
What is TXG’s upside potential, based on the analysts’ average price target?
10x Genomics Inc has 73.86% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TXG a Buy, Sell or Hold?
10x Genomics Inc has a consensus rating of Moderate Buy which is based on 6 buy ratings, 6 hold ratings and 0 sell ratings.
What is 10x Genomics Inc’s price target?
The average price target for 10x Genomics Inc is $16.36. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $26.00 ,the lowest forecast is $12.00. The average price target represents 73.86% Increase from the current price of $9.41.
The highest analyst price target is $26.00 ,the lowest forecast is $12.00. The average price target represents 73.86% Increase from the current price of $9.41.
What do analysts say about 10x Genomics Inc?
10x Genomics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of TXG?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.